Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


05.07.2021

10 Aliment Pharmacol Ther
2 Am J Gastroenterol
1 BMC Gastroenterol
1 Clin Gastroenterol Hepatol
4 Dig Dis Sci
1 Eur J Gastroenterol Hepatol
2 Gastroenterol Hepatol
5 Gastroenterology
1 Inflamm Bowel Dis
6 J Crohns Colitis
1 J Pediatr
1 PLoS One
1 Scand J Gastroenterol
1 Z Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. TURBAYNE AKB, Ward MG
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind.
    Aliment Pharmacol Ther. 2021;53:1317-1318.
    PubMed        

  2. MANLAY L, Boschetti G, Pereira B, Flourie B, et al
    Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Aliment Pharmacol Ther. 2021;53:1289-1299.
    PubMed         Abstract available

  3. LIMDI JK
    Editorial: determining disability in IBD - 'See(k) and you shall find'.
    Aliment Pharmacol Ther. 2021;53:1321-1322.
    PubMed        

  4. ROBLIN X, Nancey S, Paul S
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1319-1320.
    PubMed        

  5. WEISSHOF R, Chowers Y, Kurnik D
    Editorial: safety of thiopurines in pregnancy-considering the mother, foetus and newborn.
    Aliment Pharmacol Ther. 2021;54:88-89.
    PubMed        

  6. PUGLIESE D, Armuzzi A
    Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?
    Aliment Pharmacol Ther. 2021;54:84-85.
    PubMed        

  7. CASANOVA MJ, Chaparro M, Gisbert JP
    Editorial: withdrawal of anti-TNFalpha-are we ready for biological therapy cycling? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:86-87.
    PubMed        

  8. MEYER A, Semenzato L, Zureik M, Weill A, et al
    Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
    Aliment Pharmacol Ther. 2021;54:160-166.
    PubMed         Abstract available

  9. TASSONE D, Singh S, Sheng Ding N
    Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.
    Aliment Pharmacol Ther. 2021;54:206-207.
    PubMed        

  10. FAN D, Gearry RB
    Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?
    Aliment Pharmacol Ther. 2021;54:208-209.
    PubMed        


    Am J Gastroenterol

  11. TARGOWNIK LE, Bernstein CN, Benchimol EI, Kaplan GG, et al
    Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis.
    Am J Gastroenterol. 2021;116:1284-1293.
    PubMed         Abstract available

  12. PAPAMICHAEL K, Vande Casteele N, Jeyarajah J, Jairath V, et al
    Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
    Am J Gastroenterol. 2021;116:1007-1014.
    PubMed         Abstract available


    BMC Gastroenterol

  13. FOTEINOGIANNOPOULOU K, Karmiris K, Axiaris G, Velegraki M, et al
    The burden and management of anemia in Greek patients with inflammatory bowel disease: a retrospective, multicenter, observational study.
    BMC Gastroenterol. 2021;21:269.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  14. D'SILVA A, Fox DE, Nasser Y, Vallance JK, et al
    Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease: A Systematic Review with Meta-analysis.
    Clin Gastroenterol Hepatol. 2021 Jun 30. pii: S1542-3565(21)00698.
    PubMed         Abstract available


    Dig Dis Sci

  15. PAREKH R, Zhang X, Ungaro RC, Brenner EJ, et al
    Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease.
    Dig Dis Sci. 2021 Jun 28. pii: 10.1007/s10620-021-07104.
    PubMed         Abstract available

  16. BHAT S, Limdi JK, Cross RK, Farraye FA, et al
    Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease.
    Dig Dis Sci. 2021 Jun 26. pii: 10.1007/s10620-021-07114.
    PubMed         Abstract available

  17. RAO S, Borum ML
    Evaluating IBD Patient-Initiated Electronic Communication During the SARS-CoV-2 Pandemic: A Single-Center Study.
    Dig Dis Sci. 2021;66:2468-2469.
    PubMed        

  18. PAULIDES E, Pasma A, Erler NS, van Eijk RLA, et al
    Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease.
    Dig Dis Sci. 2021 Jun 28. pii: 10.1007/s10620-021-07118.
    PubMed         Abstract available


    Eur J Gastroenterol Hepatol

  19. RICHTER V, Bermont A, Cohen DL, Broide E, et al
    Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience.
    Eur J Gastroenterol Hepatol. 2021 Jun 29. pii: 00042737-900000000-97186.
    PubMed         Abstract available


    Gastroenterol Hepatol

  20. FORTUNY BAUZA M, Canete Pizarro F, Calm Salvans A, Calafat Sard M, et al
    Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab.
    Gastroenterol Hepatol. 2021 Jun 9. pii: S0210-5705(21)00188.
    PubMed        

  21. GONZALEZ-MUNOZA C, Briones J, Sang Park H, Garcia-Planella E, et al
    Marginal zone lymphoma under anti-TNF treatment in Crohn disease.
    Gastroenterol Hepatol. 2021 Jun 9. pii: S0210-5705(21)00193.
    PubMed        


    Gastroenterology

  22. REINISCH W
    PEG and mucosal biofilms in irritable bowel syndrome and ulcerative colitis.
    Gastroenterology. 2021 Jun 24. pii: S0016-5085(21)03167.
    PubMed        

  23. PAPA A, Gasbarrini A, Lopetuso LR
    Winter Is Coming and COVID-19 Vaccine Is Available! The Role of Gastroenterologist in Increasing COVID-19 Vaccine Acceptability Among IBD Patients.
    Gastroenterology. 2021;161:368-369.
    PubMed        

  24. ZHANG J, Hoedt EC, Liu Q, Berendsen E, et al
    Elucidation of Proteus mirabilis as a Key Bacterium in Crohn's Disease Inflammation.
    Gastroenterology. 2021;160:317-330.
    PubMed         Abstract available

  25. KELLY CR, Yen EF, Grinspan AM, Kahn SA, et al
    Fecal Microbiota Transplant is Highly Effective in Real-World Practice: Initial Results from the FMT National Registry.
    Gastroenterology. 2020 Sep 30. pii: S0016-5085(20)35221.
    PubMed         Abstract available

  26. RICCIUTO A, Aardoom M, Orlanski-Meyer E, Navon D, et al
    Predicting Outcomes in Pediatric Crohn's Disease for Management Optimization: Systematic Review and Consensus Statements From the Pediatric Inflammatory Bowel Disease-Ahead Program.
    Gastroenterology. 2021;160:403-436.
    PubMed         Abstract available


    Inflamm Bowel Dis

  27. WALLDORF J, von Arnim U, Schmelz R, Riesner-Wehner A, et al
    SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease-Fear and Desire.
    Inflamm Bowel Dis. 2021 Jun 28. pii: 6310707. doi: 10.1093.
    PubMed        


    J Crohns Colitis

  28. GUBATAN J, Rubin SJS, Bai L, Haileselassie Y, et al
    Vitamin D is Associated with alpha4beta7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Jun 28. pii: 6310486. doi: 10.1093.
    PubMed         Abstract available

  29. COX SR, Clarke H, O'Keeffe M, Dubois P, et al
    Nutrient, fibre and FODMAP intakes and food-related quality of life in patients with inflammatory bowel disease and their relationship with gastrointestinal symptoms of differing aetiologies.
    J Crohns Colitis. 2021 Jul 3. pii: 6314229. doi: 10.1093.
    PubMed         Abstract available

  30. WATANABE S, Hibiya S, Katsukura N, Kitagawa S, et al
    Importance of telomere shortening in the pathogenesis of ulcerative colitis: A new treatment from the aspect of telomeres in intestinal epithelial cells.
    J Crohns Colitis. 2021 Jun 28. pii: 6310549. doi: 10.1093.
    PubMed         Abstract available

  31. ATTAUABI M, Seidelin JB, Burisch J
    Authors' Reply to: 'COVID-19 in the IBD Population: The Need for Correct Nomenclature'.
    J Crohns Colitis. 2021;15:1080.
    PubMed        

  32. KUENZIG ME, Bitton A, Carroll MW, Kaplan GG, et al
    Inflammatory bowel disease increases the risk of venous thromboembolism in children: a population-based matched cohort study.
    J Crohns Colitis. 2021 Jun 27. pii: 6310166. doi: 10.1093.
    PubMed         Abstract available

  33. ABAKKOUY Y, Cleynen I
    The Promise of Polygenic Risk Scores as a Research Tool to Analyse the Genetics Underlying IBD Phenotypes.
    J Crohns Colitis. 2021;15:877-878.
    PubMed        


    J Pediatr

  34. LUDVIGSSON PJF, Sachs MC, Jaras J, Malmborg P, et al
    Serious Infections in Pediatric Inflammatory Bowel Disease 2002-2017 - A Nationwide Cohort Study.
    J Pediatr. 2021 Jun 30. pii: S0022-3476(21)00658.
    PubMed         Abstract available


    PLoS One

  35. CAPITANO ML, Jaiswal A, Broxmeyer HE, Pride Y, et al
    A humanized monoclonal antibody against the endothelial chemokine CCL21 for the diagnosis and treatment of inflammatory bowel disease.
    PLoS One. 2021;16:e0252805.
    PubMed         Abstract available


    Scand J Gastroenterol

  36. ZHANG CC, Voitl R, Hippchen T, Weiss KH, et al
    Evaluation of two functional CD24 polymorphisms in primary sclerosing cholangitis.
    Scand J Gastroenterol. 2020 Apr 24:1-7. doi: 10.1080/00365521.2020.1755357.
    PubMed         Abstract available


    Z Gastroenterol

  37. MULLER A, Bilger SS, Goldi A, Meinlschmidt G, et al
    [The IBD-Control questionnaire: German translation and validation of the standardized questionnaire for Patient Reported Outcome Measurement in inflammatory bowel disease].
    Z Gastroenterol. 2021 Jun 24. doi: 10.1055/a-1482-8642.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: